nach oben

International Journal of Colorectal Disease

Erschienen in:

09.02.2019 | Original Article

Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer

verfasst von: Hiroaki Miyake, Koji Murono, Hiroshi Nagata, Hiroaki Nozawa, Kazushige Kawai, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Yasutaka Shuno, Kazuhito Sasaki, Soichiro Ishihara

Erschienen in: International Journal of Colorectal Disease | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The doubling times of tumor volume and tumor markers are associated with the prognosis of liver or lung metastases from colorectal cancer (CRC). However, no studies have assessed peritoneal metastases. Therefore, we aimed to elucidate the association between doubling time and the prognosis of patients who underwent radical surgery for metachronous peritoneal metastases of CRC.

Methods

We calculated the tumor doubling times (TDT) of peritoneal metastases and serum carcinoembryonic antigen-doubling times (CEA-DT) in 33 consecutive patients who underwent radical surgery for metachronous peritoneal metastases between January 2006 and April 2017. The impact of short TDT and CEA-DT on overall survival (OS) and relapse-free survival (RFS) was retrospectively reviewed.

Results

In long TDT (> 137 days) group, the 5-year OS rate was 74.1% and median OS time was 6.6 years. In long CEA-DT (> 102 days) group, the 5-year OS rate was 50.0% and median OS time was 5.6 years. Conversely, in short TDT (≤ 137 days) and CEA-DT (≤ 102 days) group, the 5-year OS rates and median OS times were both 0.0% and 3.2 years, respectively. In the multivariate analysis, short TDT was an independent risk factor for poor RFS (P = 0.006) and OS (P = 0.010). Similarly, short CEA-DT was also a poor risk factor for RFS (P < 0.001) and OS (P = 0.012).

Conclusions

Short TDT and CEA-DT are independent risk factors for poor OS and RFS after surgery for metachronous peritoneal metastases of CRC. TDT and CEA-DT should be considered when selecting candidates for surgical resection.

Cass AW, Million RR, Pfaff WW (1976) Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 37:2861–2865CrossRefPubMed

van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, Creemers GJ, de Hingh IH (2014) Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 40:963–969. https://doi.org/10.1016/j.ejso.2013.10.001 CrossRefPubMed

Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705. https://doi.org/10.1002/bjs.8679 CrossRefPubMed

Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–267. https://doi.org/10.1200/JCO.2011.37.1039 CrossRefPubMed

Franko J, Shi Q, Meyers JP, Maughan TS, Seymour MT, Saltz L et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 17:1709–1719. https://doi.org/10.1016/S1470-2045(16)30500-9 CrossRefPubMed

Sugarbaker PH, Ryan DP (2012) Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13:e362–e369. https://doi.org/10.1016/S1470-2045(12)70210-3 CrossRefPubMed

Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065–1071. https://doi.org/10.1097/SLA.0b013e31827e9289 CrossRefPubMed

Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743. https://doi.org/10.1200/JCO.2003.04.187 CrossRefPubMed

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432. https://doi.org/10.1245/s10434-008-9966-2 CrossRefPubMed

10.

Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292CrossRef

11.

Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68. https://doi.org/10.1200/JCO.2009.23.9285 CrossRefPubMed

12.

Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011–4019CrossRefPubMed

13.

Cashin PH, Graf W, Nygren P, Mahteme H (2012) Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol 23:647–652. https://doi.org/10.1093/annonc/mdr301 CrossRefPubMed

14.

Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964. https://doi.org/10.1245/s10434-015-4387-5 CrossRefPubMed

15.

Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Therapy, Nucl Med 76:988–1000

16.

Collins VP (1962) Time of occurrence of pulmonary metastasis from carcinoma of colon and rectum. Cancer 15:387–395CrossRefPubMed

17.

Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S (2007) Long-term characteristics of 5-year survivors after liver resection for colorectal metastases. Ann Surg Oncol 14:1336–1346CrossRefPubMed

18.

Tanaka K, Shimada H, Fujii Y, Endo I, Sekido H, Togo S, Ike H (2004) Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbeck's Arch Surg 389:371–379. https://doi.org/10.1007/s00423-004-0490-y CrossRef

19.

Koga H, Moriya Y, Akasu T, Fujita S (1999) The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 25:292–296. https://doi.org/10.1053/ejso.1998.0644 CrossRefPubMed

20.

Nomura K, Miyagawa S, Harada H, Kitamura H, Seki H, Shimada R, Kobayashi A, Noike T, Kawasaki S (1998) Relationship between doubling time of liver metastases from colorectal carcinoma and residual primary cancer. Dig Surg 15:21–24. https://doi.org/10.1159/000018581 CrossRefPubMed

21.

Kito A, Tanaka K, Fujimaki H, Nakazawa M, Togo S, Minami M, Shimada H (2007) Tumor doubling time and local immune response to hepatic metastases from colorectal cancer. J Surg Oncol 96:525–533. https://doi.org/10.1002/jso.20806 CrossRefPubMed

22.

Kawaguchi K, Uehara K, Nakayama G, Fukui T, Fukumoto K, Nakamura S, Yokoi K (2016) Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection. Int J Clin Oncol 21:329–334. https://doi.org/10.1007/s10147-015-0889-1 CrossRefPubMed

23.

Tomimaru Y, Noura S, Ohue M, Okami j OK, Higashiyama M et al (2008) Metastatic tumor doubling time is an independent predictor of intrapulmonary recurrence after pulmonary resection of solitary pulmonary metastasis from colorectal cancer. Dig Surg 25:220–225. https://doi.org/10.1159/000140693 CrossRefPubMed

24.

Tanaka K, Noura S, Ohue M, Seki Y, Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O, Murata K, Kameyama M, Imaoka S (2008) Doubling time of carcinoembryonic antigen is a significant prognostic factor after the surgical resection of locally recurrent rectal cancer. Dig Surg 25:319–324. https://doi.org/10.1159/000158597 CrossRefPubMed

25.

Maetani S, Onodera H, Nishikawa T, Morimoto H, Ida K, Kitamura O, Imamura M (1998) Significance of local recurrence of rectal cancer as a local or disseminated disease. Br J Surg 85:521–525CrossRefPubMed

26.

Japanese Society for Cancer of the Colon and Rectum (2013) Japanese classification of colorectal carcinoma, 8th edn. Kane- hara & Co., Ltd., Tokyo

27.

Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y (2018) Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol 25:1646–1653. https://doi.org/10.1245/s10434-018-6436-3 CrossRefPubMed

28.

Schwartz M (1961) A biomathematical approach to clinical tumor growth. Cancer 14:1272–1294CrossRefPubMed

29.

Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y (1984) Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461–466CrossRefPubMedPubMedCentral

30.

Spratt JS Jr, Spratt TL (1964) Rates of growth of pulmonary metastases and host survival. Ann Surg 159:161–171CrossRefPubMedPubMedCentral

31.

Tanaka K, Shimada H, Miura M, Fujii Y, Yamaguchi S, Endo I, Sekido H, Togo S, Ike H (2004) Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 28:263–270. https://doi.org/10.1007/s00268-003-7088-3 CrossRefPubMed

32.

Coccolini F, Gheza F, Lotti M, Virzì S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F (2013) Peritoneal carcinomatosis. World J Gastroenterol 19:6979–6994. https://doi.org/10.3748/wjg.v19.i41.6979 CrossRefPubMedPubMedCentral

33.

Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ (2012) Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 31:397–414. https://doi.org/10.1007/s10555-012-9351-2 CrossRefPubMedPubMedCentral

34.

de Bree E, Koops W, Kröger R, van Ruth S, Witkamp AJ, Zoetmulder FA (2004) Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 86:64–73. https://doi.org/10.1002/jso.20049 CrossRef

35.

Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH (1993) Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 72:1631–1636CrossRef

36.

Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14:128–133. https://doi.org/10.1245/s10434-006-9185-7 CrossRefPubMed

37.

Pasqual EM, Bertozzi S, Bacchetti S, Londero AP, Basso SM, Santeufemia DA, Lo Re G, Lumachi F (2014) Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. Anticancer Res 34:2363–2368PubMed

38.

Marin D, Catalano C, Baski M, Di Martino M, Geiger D, Di Giorgio A, Sibio S, Passariello R (2010) 64-section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging 35:694–700. https://doi.org/10.1007/s00261-008-9464-9 CrossRefPubMed

39.

Takakura Y, Miyata Y, Okajima M, Okada M, Ohdan H (2010) Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer. Color Dis 12:e68–e75. https://doi.org/10.1111/j.1463-1318.2009.02070.x CrossRef

Titel: Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer
verfasst von: Hiroaki Miyake
Koji Murono
Hiroshi Nagata
Hiroaki Nozawa
Kazushige Kawai
Keisuke Hata
Toshiaki Tanaka
Takeshi Nishikawa
Yasutaka Shuno
Kazuhito Sasaki
Soichiro Ishihara
Publikationsdatum: 09.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: International Journal of Colorectal Disease / Ausgabe 5/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-019-03259-5

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

What’s wrong with the status quo? Plenty

MTL, a composite measure for objectively profiling hospitals on surgical performance in colorectal cancer surgery

Epidural analgesia vs systemic opioids in patients undergoing laparoscopic colorectal surgery

Study of histopathologic parameters to define the prognosis of stage II colon cancer

Pulmonary metastasis in newly diagnosed colon-rectal cancer: a population-based nomogram study

Prevalence and predictors of surgical site infections after bowel resection for Crohn’s disease: the role of dual-ring wound protector

Update Chirurgie